1Korkmaz BfJenne DE,Gauthier F. Relevance of the mouse model as a therapeutic approach for neutrophil proteinase 3-associated human diseases [J]. Int Immunopharmacol,2013,17(4);1198-1205.
2Dobric S5Popovic D, Nikolic M, et al. Anti-neutrophil cytoplasmic anti-bodies (ANCA)specific for one or several antigens;useful markers for subtypes of ulcerative colitis and associated primary sclerosing cholangitis [J]. Clin Chem Lab Med,2012,50(3):503-509.
3Qiu JY,Liu GJ,Yang XJ. The effect of serum test of patients with ulcerative colitis on diagnosis and prognosis [J]. Exp Lab Med,2010,28(2):153-154.
4Tervaert JWC,Damoiseaux J. Fifty years of antineutrophil cytoplasmic antibodies(ANCA)testing:do we need to revise the international consensus statement on testing and reporting on ANCA [J], APMIS Suppl,2013,6(127):55-59.
5Stinton LM, Bentow C,Mahler M,et al. PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC)LJ]. PLoS One,2014,9(ll):e112877.
6Deniziaut G,Ballot E. Antineutrophil cytoplasmic autoantibodies (ANCA)in autoimmune hepatitis and primary sclerosing cholangitis [J]. Clin Res Hepatol Gastroenterol,2013,37(1):105-107.
7Liu KY,Comstock SS,Shunk JM. Natural killer cell populations and cytotoxic activity in pigs fed mother's milk, formula,orformula supplemented with bovine lactoferrin [J]. Pediatr Res,2013,74(4):402-407.
8Zimecki M, Artym J, Kocrba M, et al. Effects of lactoferrin on elicitation of the antigen-specific cellular and humoral cutaneous response in mice [J]. Postepy Hig Med Dosw,2012,66:16-22.
9Chocova Z,Hruskova Z,Mareckova H,et al. Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters[J]. Clin Rheumatol,2015,34(1):107-115.
10Spoerl D,Pers YM, Jorgensen C. Anti-neutrophil cytoplasmic anti-bodies in rheumatoid arthritis: two case re- ports and review of literature[J]. Allergy Asthma Clin Immunol,2012,8(66):19-20.
